Plus Products Ranked #1 Edibles Brand in California in Q3 2018
Q3 2018 Retail Sales Data Confirms Growing Market Penetration
SAN MATEO, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Plus Products Inc. (CSE: PLUS) (the “Company” or “Plus Products”) today announced that, according to both BDS Analytics (bdsanalytics.com) and Headset (headset.io) Q3 2018 retail sales data, PLUS™ is the #1 best-selling cannabis-infused edibles brand in California.
PLUS™ Sour Watermelon Gummies and PLUS™ Blackberry & Lemon Gummies are the #1 and #2 best-selling branded products, respectively, across all categories in California including flower, vaporizers, edibles, and topicals.
“We are grateful to the California consumers who have made PLUS the leading cannabis product in California, the largest and most competitive cannabis market in the world,” said CEO, Jake Heimark. “This has been a big year for Plus Products as we expand our portfolio and look to broaden our geographic reach and we remain committed to offering our customers products they can trust that provide consistent experiences in delicious formats.”
According to BDS Analytics, PLUS unit sales have grown 97% from Q2 2018 to Q3 2018, improving its edibles market position from #4 to #1 in retail value of sales.
About Plus Products
The Company is a branded products manufacturer based in California. Its products consist of cannabis-infused edibles, which it sells to both the regulated medicinal and adult-use recreational markets. PLUS™ is currently one of the fastest-growing edible brands in California with several top-selling products.
All products under the PLUS brand are made with high-quality ingredients and produced in the Company’s dedicated 12,000 foot, food-safe cannabis manufacturing facility in Adelanto, California, staffed with chemists and food scientists. Plus Products received the eighth temporary manufacturing license in California.
The Company’s mission is to make cannabis safe and approachable — that starts with manufacturing high-quality products delivering consistent experiences.
For further information contact:
Director of Investor Relations
Tel +1 650.223.5478
Tel +1 415.307.1380
The CSE does not accept responsibility for the adequacy or accuracy of this release.
This news release contains statements and information that, to the extent that they are not historical fact, constitute "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company's management to predict all of such factors and to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.